Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab and Methylprednisolone in p53-deleted CLL
NCT00292760Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Treatment Response at 8 weeks and Unacceptable Toxicity at 16 weeks. Status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00292760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00292760.